<DOC>
	<DOC>NCT03089944</DOC>
	<brief_summary>A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-na誰ve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.</brief_summary>
	<brief_title>A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Na誰ve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1, 2, 4, 5 or 6 infection. Positive plasma HCV antibody and HCV RNA viral load greater than or equal to 1000 IU/mL at Screening. Treatmentna誰ve to any approved or investigational antiHCV medication. Participant must be documented as cirrhotic, with a ChildPugh score of less than or equal to 6. Female participant who is pregnant, breastfeeding or is considering becoming pregnant during the study, or for approximately 30 days after the last dose of study drug. Any current or historical clinical evidence of decompensated cirrhosis. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti human immunodeficiency virus antibody (HIV Ab). HCV genotype performed by the central laboratory during screening indicating genotype 3 infection or coinfection with more than one HCV genotype.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pibrentasvir</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Genotype (GT) 1, 2, 4, 5 or 6</keyword>
	<keyword>Pangenotypic</keyword>
	<keyword>Hepatitis C Virus (HCV)</keyword>
	<keyword>Glecaprevir</keyword>
	<keyword>Treatment Na誰ve</keyword>
	<keyword>Compensated Cirrhosis</keyword>
</DOC>